Johnson & Johnson Stock News

I maintain my buy rating on JNJ, citing attractive valuation, improved technicals, and a raised intrinsic value target of $184 per share. JNJ's recent earnings beat expectations, with strong Medicine and MedTech growth, a 63rd consecutive dividend hike, and healthy free cash flow. Litigation headwinds are easing, and management raised revenue guidance, though they remain cautious on earnings du...

I love luxury watches, but buying more to "earn" access to rarer models made me realize how easy it is to waste capital chasing ego-driven goals. Unlike watches, dividend growth stocks offer reliable long-term returns. A $10K McDonald's investment in 2004 would've yielded over $22K in dividends alone. History shows that strong-yielding dividend stocks, especially those in the second quintile, h...

The Dow Jones Industrial Average is an iconic stock market index. It tracks the performance of 30 of the country's most prominent publicly traded companies.

WASHINGTON--(BUSINESS WIRE)--A panel of medical experts convened by the U.S. Food & Drug Administration urged the agency to study and adopt new standards to prohibit the use of talc in consumer products such as gum, candy, rice and pharmaceuticals. Many of the experts cited the more than 30 years of studies showing an association between talc use and ovarian cancer, which led Johnson & Johnson ...

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will present at the Bernstein's 41st Annual Strategic Decisions Conference on Wednesday, May 28th, 2025. Management will participate in a Fireside Chat at 9:00 a.m. Eastern Time. A live audio webcast of the presentation will be accessible through Johnson & Johnson's Investor Relations website at www.investor.jnj.com. An archive...

Focus on dividend sustainability and business quality, not just high yield, to build reliable passive income. Avoid overexposure to cyclical sectors; prioritize companies with resilient dividends through recessions, like consumer staples and pharma. Dividend growth and low payout ratios are key for long-term compounding; patience is essential for meaningful yield on cost.

ODAC recommendation based on the positive progression-free survival and clinical benefit in the Phase 3 AQUILA study If approved, DARZALEX FASPRO® would be the first treatment to potentially delay or prevent progression to multiple myeloma RARITAN, N.J. , May 20, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisor...

Johnson & Johnson (NYSE:JNJ ) RBC Capital Markets Global Healthcare Conference May 20, 2025 1:35 PM ET Corporate Participants Joe Wolk - EVP, Chief Financial Officer Conference Call Participants Shagun Singh - RBC Capital Markets Shagun Singh Hello everyone, I am Shagun Singh, Senior Research Analyst at RBC, and I'm very happy to host the next session with Johnson & Johnson. Joining us from the...